Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7 TCR Gene Therapy in HPV-16+ Cancers
NCT02858310Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2017
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of KITE-439 in cancer, sponsored by National Cancer Institute. Started Jan 2017; status: completed.
02
Drugs
KITE-439
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02858310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858310.